AILBRY - Article Search
Serach over 250 million academic articles from all areas of study
Results for 'Ronald van Vollenhoven'
:
OP0296 THE 2021 DORIS DEFINITION OF REMISSION IN SLE – FINAL RECOMMENDATIONS FROM AN INTERNATIONAL TASK FORCE
Publication Year: 2021
DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1192
Abstract:
Add to Library
Authors:
Ronald van Vollenhoven
George Βertsias
Andrea Doria
David Isenberg
Eric F. Morand
Michelle Petri
Bernardo A. Pons‐Estel
Anisur Rahman
Manuel F. Ugarte‐Gil
Alexandre E. Voskuyl
Laurent Arnaud
Ian N Bruce
Ricard Cervera
N. Costedoat‐Chalumeau
Caroline Gordon
Frédéric Houssiau
Marta Mosca
M. Schneider
Marcia M. Ward
Cynthia Aranow
Optimising Patient Outcomes Throughout the Rheumatoid Arthritis Patient Journey: The Exception, the Standard, and the Rule
Publication Year: 2016
DOI: https://doi.org/10.33590/emjrheumatol/10314540
Abstract:
Add to Library
Authors:
LB0004 EFFICACY AND SAFETY OF DEUCRAVACITINIB, AN ORAL, SELECTIVE, ALLOSTERIC TYK2 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 2, RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED STUDY
Publication Year: 2022
DOI: https://doi.org/10.1136/annrheumdis-2022-eular.5020a
Abstract:
Add to Library
Authors:
E. Morand
Margaret N. Pike
JT Merrill
Ronald van Vollenhoven
V. P. Werth
Coburn Hobar
Nikolay Delev
V. Shah
Brian J. Sharkey
T. Wegman
Ian M. Catlett
Sibabrata Banerjee
Shalabh Singhal
THU0167 SAFETY PROFILE OF UPADACITINIB IN RHEUMATOID ARTHRITIS: INTEGRATED ANALYSIS FROM THE SELECT PHASE 3 CLINICAL PROGRAM
Publication Year: 2019
DOI: https://doi.org/10.1136/annrheumdis-2019-eular.3403
Abstract:
Add to Library
Authors:
Stanley Cohen
Ronald van Vollenhoven
Kevin Winthrop
Cristiano A. F. Zerbini
Yoshiya Tanaka
Louis Bessette
Yihan Li
Nasser Khan
Barbara A. Hendrickson
Gerd R Burmester
OP0137 EFFICACY AND SAFETY OF TELITACICEPT, A NOVEL BLYS/APRIL DUAL INHIBITOR, IN PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: A PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED 52-WEEK STUDY
Publication Year: 2023
DOI: https://doi.org/10.1136/annrheumdis-2023-eular.1727
Abstract:
Add to Library
Authors:
L. Wang
Jiatong Li
Dong Xu
Jianmin Fang
Ronald van Vollenhoven
F. Zhang
OP0193 BIIB059, A HUMANIZED MONOCLONAL ANTIBODY TARGETING BDCA2 ON PLASMACYTOID DENDRITIC CELLS (PDC), SHOWS DOSE-RELATED EFFICACY IN THE PHASE 2 LILAC STUDY IN PATIENTS (PTS) WITH ACTIVE CUTANEOUS LUPUS ERYTHEMATOSUS (CLE)
Publication Year: 2020
DOI: https://doi.org/10.1136/annrheumdis-2020-eular.5743
Abstract:
Add to Library
Authors:
Victoria P. Werth
Richard Furie
Juanita Romero‐Díaz
Sandra Navarra
Kenneth Kalunian
Ronald van Vollenhoven
Fredrik Nyberg
Benjamin H. Kaffenberger
Saira Z. Sheikh
G. Radunović
Xianping Huang
H. Carroll
François Gaudreault
Adam L. Meyers
Catherine Barbey
Cristina Musselli
Nathalie Franchimont
A high incidence of disease flares in an open pilot study of infliximab in patients with refractory inflammatory myopathies
Publication Year: 2008
DOI: https://doi.org/10.1136/ard.2007.077974
Abstract:
Add to Library
Authors:
Maryam Dastmalchi
Cecilia Grundtman
Helene Alexanderson
C. Mavragani
H Einarsdottir
Sevim Barbasso Helmers
Kerstin Elvin
Mary K. Crow
Inger Nennesmo
Ingrid E. Lundberg
OP0041 MAINTENANCE OF EFFICACY AND SAFETY AND REDUCTION OF BILAG FLARES WITH USTEKINUMAB, AN INTERLEUKIN-12/23 INHIBITOR, IN PATIENTS WITH ACTIVE SYSTEMIC LUPUS ERYTHEMATOSUS (SLE): 1-YEAR RESULTS OF A PHASE 2, RANDOMIZED PLACEBO-CONTROLLED, CROSSOVER STUDY
Publication Year: 2019
DOI: https://doi.org/10.1136/annrheumdis-2019-eular.2449
Abstract:
Add to Library
Authors:
Ronald van Vollenhoven
George C. Tsokos
Robert Gordon
Kim Hung Lo
Y Irene Gregan
Kaiyin Fei
Shawn Rose
Bevra H. Hahn
Patients with early rheumatoid arthritis who smoke are less likely to respond to treatment with methotrexate and tumor necrosis factor inhibitors: Observations from the Epidemiological Investigation of Rheumatoid Arthritis and the Swedish Rheumatology Register cohorts
Publication Year: 2010
DOI: https://doi.org/10.1002/art.27758
Abstract:
Add to Library
Authors:
Saedís Saevarsdóttir
Sara Wedrén
Maria Seddighzadeh
Camilla Bengtsson
Annmarie Wesley
Staffan Lindblad
Johan Askling
Lars Alfredsson
Lars Klareskog
OP0132 EFFECT OF IBERDOMIDE ON CUTANEOUS MANIFESTATIONS IN SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A 24-WEEK, PLACEBO-CONTROLLED, PHASE 2 STUDY
Publication Year: 2021
DOI: https://doi.org/10.1136/annrheumdis-2021-eular.2181
Abstract:
Add to Library
Authors:
Victoria P. Werth
Joan T. Merrill
Richard Furie
Thomas Dörner
Ronald van Vollenhoven
Peter E. Lipsky
Michael Weiswasser
Shimon Korish
Peter Schäfer
Martin Stern
Z. Liu
Shijie Tang
Nikolay Delev
THU0197 SAFETY PROFILE OF UPADACITINIB UP TO 3 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Publication Year: 2020
DOI: https://doi.org/10.1136/annrheumdis-2020-eular.2396
Abstract:
Add to Library
Authors:
Stanley Cohen
Ronald van Vollenhoven
Jeffrey R. Curtis
Leonard H. Calabrese
Cristiano A. F. Zerbini
Yoshiya Tanaka
Louis Bessette
Casey Schlacher
T. Shaw
J. Liu
J. J. Enejosa
Yingjie Song
Gerd R Burmester
POS0220 INTEGRATED SAFETY PROFILE OF UPADACITINIB WITH UP TO 4.5 YEARS OF EXPOSURE IN PATIENTS WITH RHEUMATOID ARTHRITIS
Publication Year: 2021
DOI: https://doi.org/10.1136/annrheumdis-2021-eular.1856
Abstract:
Add to Library
Authors:
Stanley Cohen
Ronald van Vollenhoven
J. Randall Curtis
Leonard H. Calabrese
Cristiano A. F. Zerbini
Yoshiya Tanaka
Louis Bessette
Christophe Richez
I. Lagunes-Galindo
J. Liu
Heidi S. Camp
Yong Song
S. Anyanwu
Gerd R Burmester
Malignant Neoplasms in Patients With Rheumatoid Arthritis Treated With Tumor Necrosis Factor Inhibitors, Tocilizumab, Abatacept, or Rituximab in Clinical Practice
Publication Year: 2017
DOI: https://doi.org/10.1001/jamainternmed.2017.4332
Abstract:
Add to Library
Authors:
Hjalmar Wadström
Thomas Frisell
Johan Askling
Benefits of intensive resistance training in patients with chronic polymyositis or dermatomyositis
Publication Year: 2007
DOI: https://doi.org/10.1002/art.22780
Abstract:
Add to Library
Authors:
Helene Alexanderson
Maryam Dastmalchi
Mona Esbjörnsson-Liljedahl
Christina H. Opava
Ingrid E. Lundberg
Development of a New International Antiphospholipid Syndrome Classification Criteria Phase I/II Report: Generation and Reduction of Candidate Criteria
Publication Year: 2020
DOI: https://doi.org/10.1002/acr.24520
Abstract:
Add to Library
Authors:
Medha Barbhaiya
Stéphane Zuily
Yasaman Ahmadzadeh
Mary‐Carmen Amigo
Tadej Avčin
María Laura Bertolaccini
D. Ware Branch
Guilherme Ramires de Jesús
Katrien Devreese
Camille Françès
David García
Françis Guillemin
Steven R. Levine
Roger A. Levy
Michael D. Lockshin
Thomas L. Ortel
Surya V. Seshan
Maria G. Tektonidou
Denis Wahl
Rohan Willis
Ray Naden
Karen H. Costenbader
Doruk Erkan
Found 223 results in 0.166 seconds
What is Boolean Searches
Including any of the words AND
, OR
, or NOT
in any of your searches will enable
boolean search. Those words must be UPPERCASE . You can use this in all searches, including using
the search parameter, and using search filters.
This allows you to craft complex queries using those boolean operators along with parentheses and quotation marks.
Surrounding a phrase with quotation marks will search for an exact match of that phrase, after stemming and
stop-word removal (be sure to use double quotation marks — "
). Using parentheses will specify order of
operations for the boolean operators. Words that are not separated by one of the boolean operators will be
interpreted as AND
.
Behind the scenes, the boolean search is using Elasticsearch's query string query on the searchable fields (such as
title, abstract, and fulltext for works; see each individual entity page for specifics about that entity). Wildcard
and fuzzy searches using *
, ?
or ~
are not allowed; these characters will be
removed from any searches. These searches, even when using quotation marks, will go through the same cleaning as
described above, including stemming and removal of stop words.
Example Search
Search for works that mention "elmo"
and "sesame street"
, but not the words
"cookie"
or "monster"
:
"elmo" AND "sesame street" NOT "cookie" NOT "monster"